PMLiVE6d
Innovation and flexibility in long-term follow-up studies
Post-treatment follow-up of patients is not new. Traditional follow-up studies may last two to five years, while long-term ...
PMLiVE4d
Merck’s Keytruda approved by FDA as first-line malignant pleural mesothelioma treatment
Merck & Co – known as MSD outside the US and Canada – has received approval from the US Food and Drug Administration (FDA) ...
PMLiVE11d
GSK’s mRNA seasonal flu vaccine shows promise in younger and older adults
GSK has shared positive headline results for its mRNA seasonal influenza vaccine and outlined that it will now progress the ...
PMLiVE5d
Merck presents positive phase 3 results for Keytruda regimen in early-stage breast cancer
Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage ...
PMLiVE7d
Roche’s injectable PD-L1 inhibitor granted FDA approval for multiple cancer types
Roche’s injectable PD-L1 inhibitor Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) has been approved by the US Food ...
PMLiVE8d
Eli Lilly announces FDA approval for Ebglyss in moderate-to-severe atopic dermatitis
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved its targeted IL-13 inhibitor Ebglyss (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis (AD). The ...
PMLiVE13d
Gilead and AI-focused Genesis partner to develop small molecule therapies
Gilead Sciences and artificial intelligence (AI)-focused Genesis Therapeutics have entered into a collaboration aimed at developing small molecule therapies across multiple targets. The partners will ...
PMLiVE22d
Sanofi’s investigational BTK inhibitor tolebrutinib shows promise in phase 3 MS study
Sanofi’s investigational BTK inhibitor tolebrutinib has demonstrated promising results in a phase 3 study of patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS), which the ...
PMLiVE12d
Johnson & Johnson’s IL-23 inhibitor Tremfya granted FDA approval for ulcerative colitis
Johnson & Johnson’s (J&J) dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the US Food and Drug Administration (FDA) to treat adults with moderately to severely active ulcerative ...
PMLiVE12d
Sanofi/Regeneron’s Dupixent approved by MHRA to treat uncontrolled COPD
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as an add-on maintenance treatment for chronic obstructive pulmonary ...
PMLiVE14d
Regeneron’s Libtayo shows durable survival benefits in phase 3 lung cancer study
Regeneron Pharmaceuticals has shared positive five-years results from a late-stage study of Libtayo (cemiplimab) in advanced lung cancer. The phase 3 EMPOWER-Lung 1 trial compared the monoclonal ...
PMLiVE11d
The challenge of environmental management in the pharma industry
The pharmaceutical industry is committed to the development, manufacture and provision of medicines globally, a process that inevitably impacts the climate through greenhouse gases (GHG). To mitigate ...